Nestle SA, the world's biggest food and drink company, is beginning commercial talks with Australian pharmaceutical company Phosphagenics Ltd. to use one of its products for the treatment and prevention of metabolic syndrome.
The move underlines the Swiss company's determination to increase its focus on health foods, after its announcement last month that it will buy the medical nutrition unit of pharmaceutical giant Novartis for US$2.5 billion (Ђ1.88 billion).
Nestle Nutrition exercised its option under an existing commercial agreement to use Phospha-E for the treatment and prevention of metabolic syndrome, Phosphagenics said in a statement Friday, reports AP.
Metabolic syndrome is characterized by a variety of symptoms including abdominal obesity and elevated blood pressure.
The behavior of the Russian inspector satellite, which was launched in the autumn of 2017, puzzles military officials in the United States
When the bill was submitted to Congress on August 2, the reason for imposing the new sanctions on Russia was based on Russia's alleged interference in the US presidential election in 2016, but then something clicked